690632-08-7

Basic information

• Product Name: 6-BroMospiro[chroMan-2,4'-piperidin]-4-one
• Synonyms: 6-BroMospiro[chroMan-2,4'-piperidin]-4-one;6-broMo-3H-spiro[1-benzopyran-2,4'-piperidine]-4-one
• CAS NO: 690632-08-7
• Molecular Formula: C13H14BrNO2
• Molecular Weight: 296.15976
• Mol File: 690632-08-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 436.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.54±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.05±0.20(Predicted)
• CAS DataBase Reference: 6-BroMospiro[chroMan-2,4'-piperidin]-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMospiro[chroMan-2,4'-piperidin]-4-one(690632-08-7)
• EPA Substance Registry System: 6-BroMospiro[chroMan-2,4'-piperidin]-4-one(690632-08-7)

Safety Data

• Hazardous Substances Data: 690632-08-7(Hazardous Substances Data)

Usage

General Description

6-BromoSpiro[chroman-2,4'-piperidin]-4-one, also known as BMS-4, is a chemical compound with a spirocyclic structure. It is commonly used in pharmaceutical research and drug development due to its potential therapeutic properties. BMS-4 has been studied for its ability to modulate serotonin and dopamine receptors, making it a potential candidate for the treatment of neurological and psychiatric disorders. In addition, it has shown promising results in preclinical studies for its anti-inflammatory and neuroprotective effects. Its unique chemical structure and pharmacological profile make it a valuable compound for further exploration in the field of medicinal chemistry and drug discovery.

Upstream product

• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 690632-38-3 tert-butyl 6-bromo-4-oxo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxylate 
• 921760-46-5 6-bromospiro[chroman-2,4'-piperidin]-4-one hydrochloride 

Relevant articles and documents

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.